You are here

  • Home
  • Archive
  • Volume 11, Issue 12
  • Intravesical Ty21a treatment of non-muscle invasive bladder cancer induces immune responses that correlate with safety and may be associated to therapy potential

Article info

Article menu
Clinical/translational cancer immunotherapy
Original research
Intravesical Ty21a treatment of non-muscle invasive bladder cancer induces immune responses that correlate with safety and may be associated to therapy potential

Authors

  • Laurent Derré Urology Research Unit and Urology Biobank, Deptment of Urology, Centre Hospitalier Universitaire Vaudois, Lausanne, Vaud, Switzerland PubMed articlesGoogle scholar articles
  • Ilaria Lucca Urology Research Unit and Urology Biobank, Deptment of Urology, Centre Hospitalier Universitaire Vaudois, Lausanne, Vaud, Switzerland PubMed articlesGoogle scholar articles
  • Valérie Cesson Urology Research Unit and Urology Biobank, Deptment of Urology, Centre Hospitalier Universitaire Vaudois, Lausanne, Vaud, Switzerland PubMed articlesGoogle scholar articles
  • Perrine Bohner Urology Research Unit and Urology Biobank, Deptment of Urology, Centre Hospitalier Universitaire Vaudois, Lausanne, Vaud, Switzerland PubMed articlesGoogle scholar articles
  • Francois Crettenand Urology Research Unit and Urology Biobank, Deptment of Urology, Centre Hospitalier Universitaire Vaudois, Lausanne, Vaud, Switzerland PubMed articlesGoogle scholar articles
  • Sonia-Cristina Rodrigues-Dias Urology Research Unit and Urology Biobank, Deptment of Urology, Centre Hospitalier Universitaire Vaudois, Lausanne, Vaud, Switzerland PubMed articlesGoogle scholar articles
  • Florence Dartiguenave Urology Research Unit and Urology Biobank, Deptment of Urology, Centre Hospitalier Universitaire Vaudois, Lausanne, Vaud, Switzerland PubMed articlesGoogle scholar articles
  • Audrey Masnada Urology Research Unit and Urology Biobank, Deptment of Urology, Centre Hospitalier Universitaire Vaudois, Lausanne, Vaud, Switzerland PubMed articlesGoogle scholar articles
  • Carla Teixeira-Pereira Urology Research Unit and Urology Biobank, Deptment of Urology, Centre Hospitalier Universitaire Vaudois, Lausanne, Vaud, Switzerland PubMed articlesGoogle scholar articles
  • Sulayman Benmerzoug Urology Research Unit and Urology Biobank, Deptment of Urology, Centre Hospitalier Universitaire Vaudois, Lausanne, Vaud, Switzerland PubMed articlesGoogle scholar articles
  • Mathieu F Chevalier Urology Research Unit and Urology Biobank, Deptment of Urology, Centre Hospitalier Universitaire Vaudois, Lausanne, Vaud, Switzerland PubMed articlesGoogle scholar articles
  • Sonia Domingos-Pereira Urology Research Unit and Urology Biobank, Deptment of Urology, Centre Hospitalier Universitaire Vaudois, Lausanne, Vaud, Switzerland PubMed articlesGoogle scholar articles
  • Sylvain Nguyen Urology Research Unit and Urology Biobank, Deptment of Urology, Centre Hospitalier Universitaire Vaudois, Lausanne, Vaud, Switzerland PubMed articlesGoogle scholar articles
  • Lenka Polak Urology Research Unit and Urology Biobank, Deptment of Urology, Centre Hospitalier Universitaire Vaudois, Lausanne, Vaud, Switzerland PubMed articlesGoogle scholar articles
  • Anna K Schneider Urology Research Unit and Urology Biobank, Deptment of Urology, Centre Hospitalier Universitaire Vaudois, Lausanne, Vaud, Switzerland PubMed articlesGoogle scholar articles
  • Patrice Jichlinski Urology Research Unit and Urology Biobank, Deptment of Urology, Centre Hospitalier Universitaire Vaudois, Lausanne, Vaud, Switzerland PubMed articlesGoogle scholar articles
  • Beat Roth Urology Research Unit and Urology Biobank, Deptment of Urology, Centre Hospitalier Universitaire Vaudois, Lausanne, Vaud, Switzerland PubMed articlesGoogle scholar articles
  • Denise Nardelli-Haefliger Urology Research Unit and Urology Biobank, Deptment of Urology, Centre Hospitalier Universitaire Vaudois, Lausanne, Vaud, Switzerland PubMed articlesGoogle scholar articles

Citation

Derré L, Lucca I, Cesson V, et al
Intravesical Ty21a treatment of non-muscle invasive bladder cancer induces immune responses that correlate with safety and may be associated to therapy potential
Journal for ImmunoTherapy of Cancer 2023;11:e008020. doi: 10.1136/jitc-2023-008020
Online issue publication 
December 14, 2023

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY. Published by BMJ. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See https://creativecommons.org/licenses/by/4.0/.